Sugi Predict

Sugi Predict / Compounds / SCHEMBL20541883

SCHEMBL20541883

SCHEMBL20541883

CC(C)n1cnc2c(NCCc3cn(C)c4ccccc34)nc(Cl)nc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK1 P06493 3/20 0.59
▸ CDK5 Q00535 11/20 0.51
▸ CDK2 P24941 10/20 0.51
▸ CDK5R1 Q15078 10/20 0.51
▸ CCNA2 P20248 9/20 0.51
▸ CCNA1 P78396 9/20 0.51
▸ DYRK1A Q13627 8/20 0.51
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ IP6K1 Q92551 1/20 0.46
▸ AHR P35869 1/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ CCNE2 O96020 1/20 0.44
▸ CCNE1 P24864 1/20 0.44
▸ POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30579416 1.00 CDK1 (0.59) CDK1CDK5CDK2CDK5R1CCNA2
SCHEMBL17628610 0.81 CDK1 (0.79) CDK1CDK5CDK2CDK5R1CCNA2
SCHEMBL20542017 0.80 AHR (0.45) CDK1CDK5CDK2CDK5R1CCNA2
SCHEMBL30579387 0.80 AHR (0.45) CDK1CDK5CDK2CDK5R1CCNA2
SCHEMBL20541790 0.78 CDK1 (0.61) CDK1CDK5CDK2CDK5R1CCNA2
SCHEMBL2318905 0.75 CDK1 (0.62) CDK1CDK5CDK2CDK5R1CCNA2
SCHEMBL20558018 0.75 CDK1 (0.54) CDK1CDK5CDK2CDK5R1CCNA2
SCHEMBL1400442 0.74 CDK1 (1.00) CDK1CDK5CDK2DYRK1ACYP2D6
SCHEMBL20541955 0.74 CDK1 (0.58) CDK1CDK5CDK2CDK5R1CCNA2
SCHEMBL6817833 0.74 CDK1 (0.63) CDK1CDK5CDK2CDK5R1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 — — EP disclosed
EP-3612030-B1 INDOLE AHR INHIBITORS AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-12-24 — — EP disclosed
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12077542-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-09-03 — — US disclosed
CN-110831600-B Indole AHR inhibitors and uses thereof 医肯纳肿瘤学公司 2023-10-17 — — CN disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
EP-3612030-A2 INDOLE AHR INHIBITORS AND USES THEREOF Kyn Therapeutics (US) 2020-02-26 — — EP disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
CN-110831600-A Indole AHR inhibitors and uses thereof 金恩医疗公司 2020-02-21 — — CN disclosed
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2018-11-15 — — US disclosed
WO-2018195397-A2 INDOLE AHR INHIBITORS AND USES THEREOF KYN THERAPEUTICS (US) 2018-10-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885
US-10570138-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885
US-11358969-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885
US-10689388-B1 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885
US-12077542-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback